Isabell A. Sesterhenn
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Isabell A. Sesterhenn has a total of 37 co-authors. Here are the top co-authors by number of shared publications:
- Denise Y. Young
Center for Prostate Disease Research, Murtha Cancer Center Research Program, Department of Surgery, Uniformed Services University of the Health Sciences, Bethesda, Maryland
78 shared publications - Cara C. Schafer
Center for Prostate Disease Research, Murtha Cancer Center Research Program, Department of Surgery, Uniformed Services University of the Health Sciences, Bethesda, Maryland
77 shared publications - Darryl Nousome
CCR Collaborative Bioinformatics Resource, Office of Science and Technology Resources, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
77 shared publications - Gregory T. Chesnut
Center for Prostate Disease Research, Murtha Cancer Center Research Program, Department of Surgery, Uniformed Services University of the Health Sciences, Bethesda, MD
77 shared publications - Jiji Jiang
Center for Prostate Disease Research, Murtha Cancer Center Research Program, Department of Surgery, Uniformed Services University of the Health Sciences, Bethesda, Maryland
77 shared publications - Sally Elsamanoudi
Center for Prostate Disease Research, Murtha Cancer Center Research Program, Department of Surgery, Uniformed Services University of the Health Sciences, Bethesda, Maryland
77 shared publications
Latest Publications
- Open Access
- 1 August 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Immunologic Assessment of Tumors from a Race-matched Military Cohort Identifies Mast Cell Depletion as a Marker of Prostate Cancer Progression
Supplementary Table S2 shows gene expression evaluated as a continuous variable and by median and Youden index cutoffs for BCR-free and metastasis-free survival.
- 1 August 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Immunologic Assessment of Tumors from a Race-matched Military Cohort Identifies Mast Cell Depletion as a Marker of Prostate Cancer Progression
Supplementary Table S2 shows gene expression evaluated as a continuous variable and by median and Youden index cutoffs for BCR-free and metastasis-free survival.
- Open Access
- 1 August 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Immunologic Assessment of Tumors from a Race-matched Military Cohort Identifies Mast Cell Depletion as a Marker of Prostate Cancer Progression
Supplementary Table S3 shows Total TILs and individual cell type vs TILs scores evaluated as a continuous variable and by median and Youden index cutoffs for BCR-free and metastasis-free survival.
- 1 August 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Immunologic Assessment of Tumors from a Race-matched Military Cohort Identifies Mast Cell Depletion as a Marker of Prostate Cancer Progression
Supplementary Table S3 shows Total TILs and individual cell type vs TILs scores evaluated as a continuous variable and by median and Youden index cutoffs for BCR-free and metastasis-free survival.
- Open Access
- 1 August 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S8 from Immunologic Assessment of Tumors from a Race-matched Military Cohort Identifies Mast Cell Depletion as a Marker of Prostate Cancer Progression
Supplementary Figure S8 shows non-significant relative cell type scores by Dx Age Group.
- 1 August 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S8 from Immunologic Assessment of Tumors from a Race-matched Military Cohort Identifies Mast Cell Depletion as a Marker of Prostate Cancer Progression
Supplementary Figure S8 shows non-significant relative cell type scores by Dx Age Group.
- Open Access
- 1 August 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Immunologic Assessment of Tumors from a Race-matched Military Cohort Identifies Mast Cell Depletion as a Marker of Prostate Cancer Progression
Supplementary Figure S4 shows non-significant relative cell type scores by GG.
- 1 August 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from Immunologic Assessment of Tumors from a Race-matched Military Cohort Identifies Mast Cell Depletion as a Marker of Prostate Cancer Progression
Supplementary Figure S4 shows non-significant relative cell type scores by GG.
- Open Access
- 1 August 2023
- Published by American Association for Cancer Research (AACR)
FIGURE 4 from Immunologic Assessment of Tumors from a Race-matched Military Cohort Identifies Mast Cell Depletion as a Marker of Prostate Cancer Progression
Significant relative cell type scores for clinicopathologic variables. Relative cell type scores that demonstrated significance for GG (A), Gleason sum (B), metastasis (C), age at diagnosis group (D), and PSA (E) at diagnosis group are shown. Mann–Whitney U test (A, C) or Kruskal–Wallis test followed by Dunn multiple comparisons post-hoc test (B, D, E) were used to determine significance, as indicated by listed P values below 0.05. Each dot represents a patient score, and error bars correspond to mean ± SD.
- 1 August 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFIGURE 4 from Immunologic Assessment of Tumors from a Race-matched Military Cohort Identifies Mast Cell Depletion as a Marker of Prostate Cancer Progression
Significant relative cell type scores for clinicopathologic variables. Relative cell type scores that demonstrated significance for GG (A), Gleason sum (B), metastasis (C), age at diagnosis group (D), and PSA (E) at diagnosis group are shown. Mann–Whitney U test (A, C) or Kruskal–Wallis test followed by Dunn multiple comparisons post-hoc test (B, D, E) were used to determine significance, as indicated by listed P values below 0.05. Each dot represents a patient score, and error bars correspond to mean ± SD.
- Open Access
- 1 August 2023
- Published by American Association for Cancer Research (AACR)
TABLE 1 from Immunologic Assessment of Tumors from a Race-matched Military Cohort Identifies Mast Cell Depletion as a Marker of Prostate Cancer Progression
TABLE 1 from Immunologic Assessment of Tumors from a Race-matched Military Cohort Identifies Mast Cell Depletion as a Marker of Prostate Cancer Progression
- 1 August 2023
- Published by American Association for Cancer Research (AACR)
Open AccessTABLE 1 from Immunologic Assessment of Tumors from a Race-matched Military Cohort Identifies Mast Cell Depletion as a Marker of Prostate Cancer Progression
TABLE 1 from Immunologic Assessment of Tumors from a Race-matched Military Cohort Identifies Mast Cell Depletion as a Marker of Prostate Cancer Progression
- Open Access
- 1 August 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Immunologic Assessment of Tumors from a Race-matched Military Cohort Identifies Mast Cell Depletion as a Marker of Prostate Cancer Progression
Supplementary Figure S2 shows non-significant relative cell type scores by race.
- 1 August 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Immunologic Assessment of Tumors from a Race-matched Military Cohort Identifies Mast Cell Depletion as a Marker of Prostate Cancer Progression
Supplementary Figure S2 shows non-significant relative cell type scores by race.
- Open Access
- 1 August 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S6 from Immunologic Assessment of Tumors from a Race-matched Military Cohort Identifies Mast Cell Depletion as a Marker of Prostate Cancer Progression
Supplementary Figure S6 shows non-significant relative cell type scores by Gleason Sum.
- 1 August 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S6 from Immunologic Assessment of Tumors from a Race-matched Military Cohort Identifies Mast Cell Depletion as a Marker of Prostate Cancer Progression
Supplementary Figure S6 shows non-significant relative cell type scores by Gleason Sum.
- Open Access
- 1 August 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S11 from Immunologic Assessment of Tumors from a Race-matched Military Cohort Identifies Mast Cell Depletion as a Marker of Prostate Cancer Progression
Supplementary Figure S11 shows BCR-free and Metastasis-free survival for cell types dichotomized by median cutoffs.
- 1 August 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S11 from Immunologic Assessment of Tumors from a Race-matched Military Cohort Identifies Mast Cell Depletion as a Marker of Prostate Cancer Progression
Supplementary Figure S11 shows BCR-free and Metastasis-free survival for cell types dichotomized by median cutoffs.
- Open Access
- 1 August 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from Immunologic Assessment of Tumors from a Race-matched Military Cohort Identifies Mast Cell Depletion as a Marker of Prostate Cancer Progression
Supplementary Figure S5 shows non-significant relative cell type scores by metastasis status.
- 1 August 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from Immunologic Assessment of Tumors from a Race-matched Military Cohort Identifies Mast Cell Depletion as a Marker of Prostate Cancer Progression
Supplementary Figure S5 shows non-significant relative cell type scores by metastasis status.